In prostate cancer PDX models, the intratumoral administration of TMEM16A shRNA significantly suppresses tumor growth, achieving inhibition rates of up to 70% in orthotopic nude mice [1]. This evidence concerns the gene ANO1 and Familial prostate cancer.